July 01, 2024
ANTERIS PRESS RELEASES
ANTERIS PRESS RELEASES
- 2024
- 2023
- 2022
- 2021
- 2020
- 2019-2017 Timeline
- Clinical & Program Updates
- Corporate & Financial News
Anteris and v2vmedtech, inc., a structural heart company developing a next generation Transcatheter Edge to Edge Repair (TEER) system for mitral and tricuspid valve regurgitation today announced they have reached concept lock on the first phase of the system.
June 20, 2024
Anteris announces the latest cohort of 13 patients was undertaken to finalise and confirm the performance of the ComASUR™ Delivery System prior to commencement of the DurAVR™ THV pivotal, registration study (Phase 3). The balloon expandable ComASUR™ Delivery System enabled controlled deployment and accurate placement of the DurAVR™ THV, facilitating precise alignment with the patients’ native aortic valve. 30-day data from this recent cohort demonstrated improved haemodynamic (blood flow) performance relative to earlier favourable clinical results reported in the DurAVR™ THV FIH Study (Cohorts 1-4) in addition to validating the predictability of the ComASUR™ Delivery System.
June 18, 2024
Anteris today announced that following a pre-submission meeting with the US FDA, the agency has indicated support for key study design aspects.
June 13, 2024
Anteris today announced a summation of the Company’s presentation at the New York Valves annual Conference held at the Jacob K. Javits Convention Center in New York City.
June 11, 2024
Anteris today announced a summation of the Company’s presentation at the New York Valves annual Conference held at the Jacob K. Javits Convention Center in New York City.
May 15, 2024
Anteris announces it has successfully performed a difficult to treat “Valve-in-Valve-in-Valve” procedure. The patient, who was receiving a third valve replacement (or valve-in-valve-in-valve) has been successfully treated at the Karolinska University Hospital in Stockholm, Sweden by Dr Andreas Rück, Dr Magnus Settergren and Dr Nawzad Saleh.
Mar 12, 2024
Anteris today announced further data from the DurAVR™ First-In-Human Study and US Early Feasibility Study (EFS).
The data substantiates the paradigm shifting haemodynamic (blood flow) results reported to date with the DurAVR™ valve, a new class of biomimetic transcatheter heart valve (THV) designed to restore normal blood flow in aortic stenosis, a serious, life-threatening heart condition which occurs when there is a narrowing of the aortic valve.
Jan 22, 2024
Anteris is pleased to announce the successful completion of three new valve-in-valve (ViV) cases using DurAVR™, a first-in-class biomimetic transcatheter heart valve.
September 04, 2024
Anteris Technologies Ltd (ASX: AVR) (ATL or the Company) refers to its announcement made on 2 September 2024 that the Supreme Court of Queensland had approved the convening of the Scheme Meetings and the distribution of the Scheme Booklet in relation to the share and option schemes of arrangement between ATL and its shareholders (Share Scheme) and ATL and its optionholders (Option Scheme, and together with the Share Scheme, the Schemes).
September 02, 2024
Anteris Technologies Ltd (ASX: AVR) (ATL or the Company) is pleased to provide an update in relation to the share and option schemes of arrangement between ATL and its shareholders (Share Scheme) and ATL and its optionholders (Option Scheme, and together with the Share Scheme, the Schemes), pursuant to which Anteris Technologies Global Corp. (Holdco) will acquire 100% of ATL’s issued shares, ATL optionholders will exchange their options in ATL for equivalent securities in Holdco, and Holdco will become the new ultimate parent company of the Anteris Group effectively redomiciling the Company to the United States (Re-domiciliation), as previously announced by ATL to ASX on 13 August 2024.
August 22, 2024
Anteris Technologies Ltd (ASX: AVR) (Anteris or the Company) releases its Appendix 4D – Half Yearly (HY24) Financial Report and commentary for the period ended 30 June 2024.
August 13, 2024
Anteris has entered into a scheme implementation deed with Anteris Technologies Global Corp. (Holdco) to pursue a re-domiciliation of ATL and its subsidiaries (Anteris Group) from Australia to the United States of America by way of proposed schemes of arrangement with its shareholders under Part 5.1 of the Corporations Act 2001 (Cth) (Share Scheme) and its optionholders (Option Scheme) (together, the Schemes).
July 31, 2024
Anteris submits the following Activities Report and Appendix 4C – Quarterly Cash Flow statement for the quarter ended 30 June 2024 (Q2).
July 24, 2024
July 01, 2024
Anteris submits Change of Director's Interest Notice.
May 29, 2024
Anteris is pleased to announce the following results from the Annual General Meeting held on 29 May 2024. At today’s Annual General Meeting all Resolutions put to Shareholders were passed by a Poll.
May 29, 2024
Anteris is pleased to provide the attached Chairman’s Address and Chief Executive Officer Presentation to the Annual General Meeting being held today
Apr 29, 2024
The Annual General Meeting of Anteris Technologies Ltd will be held via live webcast, and physically at Sheraton Grand Sydney Hyde Park, 161 Elizabeth Street, Sydney NSW 2000, at 10:00 a.m. AEST on Wednesday 29 May 2024.
Apr 18, 2024
Anteris submits the following Activities Report and Appendix 4C – Quarterly Cash Flow statement for the quarter ended 31 March 2024 (Q1).
Apr 15, 2024
Anteris submits the following Corporate Governance Statement.
Apr 15, 2024
Anteris is pleased to provide a copy the 2023 Annual Report.
Apr 10, 2024
Anteris has placed one million new ordinary shares at $23 each, raising $23 million in gross proceeds. The funds raised will primarily be used preparing for the DurAVR™ transcatheter heart valve’s FDA pivotal study, a key step to gain regulatory clearance for the US market. The funds will also be used for strategic initiatives, valve-in-valve trials and general working capital.
Apr 02, 2024
Anteris submits Change of Director's Interest Notice.
Feb 28, 2024
Anteris releases its Appendix 4E Preliminary final report and commentary for the year ended 31 December 2023.
Jan 31, 2024
Anteris submits the following Activities Report and Appendix 4C – Quarterly Cash Flow statement for the quarter ended 31 December 2023 (Q4).
Jan 9, 2024
Anteris is pleased to provide a copy of an Investor Update Presentation to be held today at the Annual J.P. Morgan Healthcare Conference.
- Clinical & Program Updates
- Corporate & Financial News
Nov 21, 2023
Anteris reports 30-day data from the US Early Feasibility Study (EFS) for DurAVR™ Transcatheter Heart Valve (THV). The preliminary results 30 days post-procedure included data from 12 out of the 15 enrolled patients (three patients awaiting scheduling).
Oct 25, 2023
Anteris reports data from its US Early Feasibility Study (EFS) for DurAVR™ Transcatheter Heart Valve (THV), a new class of aortic valve replacement (AVR) and the world’s only biomimetic, single-piece transcatheter aortic valve.
Oct 17, 2023
Anteris reports completing enrolment in its FDA approved Early Feasibility Study (EFS or the Study) in the United States. DurAVR™ THV is a new class of biomimetic valve and the world’s only balloonexpandable, single-piece transcatheter aortic valve. The EFS is an essential step towards receiving FDA clearance in the US for commercialization of this innovative medical technology.
Aug 14, 2023
Anteris Technologies reported today that DurAVR™ THV, a new class of biomimetic valve and the world’s only balloon-expandable, single-piece transcatheter aortic valve, was implanted in a second successful Valve-in-Valve (ViV) procedure as part of Health Canada’s Special Access Program (SAP).
Aug 09, 2023
Anteris Technologies Ltd reported today that DurAVR™ Transcatheter Heart Valve (THV), a new class of aortic valve replacement (AVR) and the world’s only biomimetic, single-piece transcatheter aortic valve, was used to successfully treat patients as part of the DurAVR™ THV Early Feasibility Study (EFS or the Study) in the United States. The EFS is an essential step towards receiving FDA approval in the US and commercialisation of this innovative medical technology.
July 31, 2023
Anteris Technologies Ltd reported today that for the first time, DurAVR™ THV, a new class of biomimetic valve and the world’s only balloon-expandable, single-piece transcatheter aortic valve, was used in a valve-in-valve (ViV) procedure as part of Health Canada’s Special Access Program (SAP).
June 13, 2023
Anteris Technologies Ltd recently presented new patient data at the TVT conference. The results show DurAVR™ THV maintained excellent haemodynamic performance at 30 days, as previously reported with this patient cohort at 48 hours post-procedure.
June 09, 2023
Anteris Technologies Ltd (Anteris or the Company) (ASX: AVR) presents the latest data from the DurAVR™ First-In-Human Study at the TVT Conference. Results show DurAVR™ THV continues to maintain excellent haemodynamic performance as previously reported at one year and 30 day time points.
May 31, 2023
Anteris Technologies Ltd announces DurAVR™ THV delivers exceptional haemodynamic outcomes in a third patient cohort, comprising seven First-in-Human Study participants and one compassionate case, further validating results previously reported.
May 22, 2023
Anteris Technologies Ltd is delighted to announce the publication of “Early safety and feasibility of a first-in-class biomimetic transcatheter aortic valve (DurAVR™)” in EuroIntervention. The publication reports interim results from the DurAVR™ First-in-Human (FIH) Study designed to evaluate the safety and efficacy of the DurAVR™ THV, a first-in-class biomimetic valve, in the treatment of patients with symptomatic severe aortic stenosis.
May 17, 2023
Anteris Technologies Ltd is pleased to announce that the United States Patent and Trademark Office has issued another utility patent to the Company for the novel DurAVR™ transcatheter heart valve (THV).
April 19, 2023
Anteris Technologies Ltd is pleased to announce that the Company has entered an agreement with v2vmedtech, inc. (“Agreement”) to partner with leading physicians to develop an innovative heart valve repair device for the minimally invasive treatment of mitral and tricuspid valve regurgitation (“Devices”) – also known as a leaky valve – a market expected to be $A4.1 Bn by 20281.
April 12, 2023
Anteris Technologies Ltd is pleased to announce that the United States Patent and Trademark Office has issued a utility patent to the Company for the novel DurAVR™ transcatheter heart valve (THV).
Feb 09, 2023
Anteris Technologies Ltd is pleased to announce that the United States Food and Drug Administration (FDA) has granted expanded approval for the DurAVR™ THV System in Subjects with Severe Aortic Stenosis: Early Feasibility Study (EFS).
Jan 16, 2023
Anteris Technologies Ltd is delighted to announce 12-month results from the DurAVR™ First-in-Human (FIH) Study designed to evaluate the safety and efficacy of the DurAVR™ THV in patients with symptomatic severe aortic stenosis.
Oct 26, 2023
Anteris has raised $40 million with the issue of two million new ordinary shares (New Shares) at $20 per New Share (Placement). The funds will be used for preparation for the FDA Pivotal trial of the Company’s DurAVR™ THV for treating severe aortic stenosis, continued Valve-in-Valve trials and general working capital expenses.
Sep 12, 2023
Anteris Technologies announced today that Wayne Paterson, the Chief Executive Officer of Anteris will present at the Cantor Fitzgerald Annual Global Healthcare Conference in New York, NY on Tuesday, September 26, 2023, at 2:45 p.m. Eastern Time.
Aug 09, 2023
Anteris Technologies Ltd (ASX: AVR) (“Anteris” or the “Company”) announced today that it has established a sponsored Level 1 American Depository Receipt (ADR) program in the United States. The ADR program has been set up to improve U.S. investor access to Anteris ordinary shares.
The ADRs representing Anteris ordinary shares will trade on the over-the-counter (OTC) market with the ticker symbol ANTTY. Deutsche Bank has been appointed as the Depositary Bank for Anteris Technologies’ ADR program.
May 29, 2023
Anteris Technologies Ltd is pleased to provide the attached Chairman’s Address and Chief Executive Officer Presentation to the Annual General Meeting being held today.
Feb 09, 2023
Anteris Technologies Ltd has placed 1.458 million new ordinary shares in the Company (New Shares) to various sophisticated and professional investors at an issue price of $24.00 per New Share1, raising $35 million (Placement).
Feb 09, 2023
Anteris Technologies Ltd is pleased to announce that the Company has entered into a non-binding agreement with Yorkville Advisors Global, LP (Investor) to provide a $50 million SEPA facility to Anteris.
- Clinical & Program Updates
- Corporate & Financial News
Sep 19, 2022
Anteris Technologies Ltd presents preliminary results demonstrating for the first-time restoration of normal pre-disease blood flow after aortic valve replacement at Transcatheter Cardiovascular Therapeutics (TCT) conference, the world's foremost meeting of interventional cardiologists.
July 11, 2022
Anteris Technologies Ltd reports the 30-day follow-up results on the second cohort of (eight) patients showed clinically significant improvements.
June 21, 2022
Anteris Technologies Ltd is pleased to announce the 6 month follow up of our first cohort of 5 patients. The 6 month follow up is informal (formal follow ups according to the study protocol are 30 days and 1 year). All patients are doing very well and in fact have shown marked improvements since the 3 month follow up.
May 31, 2022
Anteris Technologies Ltd reports eight more patients were successfully treated last week, as part of the ongoing first-in-human DurAVR™ THV study conducted at the Tbilisi Heart and Vascular Clinic, Tbilisi, Georgia.
May 25, 2022
As outlined by Mr Wayne Paterson, Chief Executive Officer at the Annual General Meeting, Anteris Technologies Ltd (the Company) is pleased to announce that we have commenced treating the second cohort of patients as part of the first-in-human study for the Company’s DurAVR™ transcatheter heart valve system.
Jan 24, 2022
Anteris Technologies Ltd reports the first-in-human DurAVR™ THV study met or exceeded its interim study objectives.
Mar 22, 2022
Anteris Technologies Ltd announces the Company has entered a binding agreement to place 1,840,000 new Ordinary Shares (New Shares) raising USD 20 million ($A 28 million) to Perceptive Life Sciences Master Fund, Ltd and managed by Perceptive Advisors (Perceptive) at $A15 a share, representing a 20% discount to the closing price on 28 February 2022.
Feb 08, 2022
Anteris Technologies Ltd announces that it has received a confidential, non-binding proposal to negotiate a letter of intent, which letter sets out a proposal to merge with NASDAQ-listed special purpose acquisition company Medicus Sciences Acquisition Corp. (MSAC). MSAC currently has no commercial operations and was established as a blank cheque company for the purpose of, amongst other things, effecting a merger, share exchange or business combination with one or more businesses.
- Clinical & Program Updates
- Corporate & Financial News
Nov 22, 2021
Anteris Technologies Ltd reports successfully implanting five TAVR patients during the week of 14 November 2021 in a first-in-human (FIH) study to assess the DurAVR™ THV system for treating severe aortic stenosis. The study was carried out at the Tbilisi Heart and Vascular Clinic, Tbilisi, Georgia.
Apr 27, 2021
Anteris Technologies Ltd reports reaching concept lock on critical components of its ComASUR™ Transfemoral Delivery System. Most importantly, the novel commissural alignment component which gives the physician the ability to align the commissures of the replacement valve to the native valve is now fully functional. This aspect of Transcatheter Aortic Valve Replacement (TAVR)
Mar 29, 2021
Anteris Technologies Ltd reports results from the Company’s anti-calcification study indicating its ADAPT® treated tissue has superior anti-calcification attributes compared with tissues used in competitor valves.
Oct 27, 2021
Anteris Technologies Ltd has placed 625,000 new Ordinary Shares (New Shares) to funds managed or advised by Melbourne-based global investor L1 Capital (Investors), including L1 Long Short Fund Limited, at $8.00 each raising $5 million. The placement price represents a 5% discount to the closing spot price.
Aug 02, 2021
Anteris Technologies Ltd is pleased to announce the placement of 1.125m new Ordinary shares (New Shares) to sophisticated investors at $8.00 per share raising a total $9 million. The proceeds of the Placement will be used for working capital predominantly related to the development of DurAVR™TM, the Company’s 3D single-piece aortic valve for the treatment of Aortic Stenosis.
Jan 20, 2021
Anteris Technologies Ltd announces that the first tranche closing under the convertible security and share purchase agreement to Mercer Street Global Opportunity Fund, LLC (Mercer), as announced to ASX on 6 January 2021, has occurred today, raising $2.5M before costs.
Jan 06, 2021
Anteris Technologies Ltd announces a funding package of up to $20M including $2.5M to be initially drawn down upon completion of the conditions precedent (see further details below). The funding provides additional working capital as Anteris advances the development of DurAVR™, its 3D single-piece aortic valve for the treatment of aortic stenosis.
- Clinical & Program Updates
- Corporate & Financial News
Nov 23, 2020
Anteris Technologies Ltd is pleased to advise that its 3D single-piece aortic valve DurAVR™ has been selected as a “Best Innovation” at the PCR London Valves 2020 virtual conference, with data from the company’s first-in-human trial to be presented.
Nov 10, 2020
Anteris Technologies Ltd reports interim results from the Company’s anti-calcification study indicating its ADAPT® treated tissue has superior anti-calcification attributes compared with tissues used in competitor valves.
Sep 08, 2020
Anteris Technologies Ltd a structural heart company advancing the DurAVR™ valve, a novel single-piece 3D aortic valve replacement solution, has been granted a patent in the United States for the sterilisation method employed in the manufacture of the Company’s ADAPT® tissue.
Mar 27, 2020
Admedus Limited announces the first implantation of its ADAPT® treated single-piece 3D aortic valve in a patient with aortic stenosis.
Jan 22, 2020
Admedus Limited announces approval for first-in-human surgical aortic valve replacement (SAVR) trial of its proprietary ADAPT® single-piece 3D aortic valve at the Leuven University Hospitals. The UZ Leuven Medical Ethics Committee approved the clinical trial protocol.
Dec 30, 2020
Anteris Technologies Ltd, a structural heart company advancing the DurAVR™ valve, a novel single-piece 3D aortic valve replacement solution, is pleased to announce the successful completion of a placement of 316,954 fully paid Ordinary Shares at $3.37 per new share, raising a total of $1.1m.
CONTACT U.S. INVESTOR RELATIONS
Malini Chatterjee, PhD. Managing Director
Blueprint Life Science Group
mchatterjee@bplifescience.com